31 articles on CAR-T, lymphoma and stem-cell transplant, published by the hospitals we work with — and linked to the original.
How this page works.
Each card below links to an article published by that hospital on its own website. We translate the headline and summary into your language and send you to the original for the full text, the imaging and the clinician's own account. Nothing here is rewritten or republished, and no article on this page is a substitute for medical advice about your own case.
Beijing · GOBROAD Medical Group
A haematology and transplant centre whose CAR-T work runs from paediatric T-ALL to refractory myeloma, presented each year at APBMT and IMS.
Twenty-three children with relapsed or refractory T-ALL went from CD7 CAR-T straight into allogeneic transplant; 84.8% were relapse-free at two years.
Patient storyA 53-year-old with gastric cancer and peritoneal spread saw his PCI score fall from 9 to 0 within eight months, then reached surgery — still controlled at 48 months.
Patient storyPrimary CNS lymphoma, eleven years and counting — a case built on transplanting with residual disease and adding CAR-T when the disease came back.
Patient storyAfter a failed first CAR-T attempt and a haploidentical transplant, a 29-year-old with B-ALL has been in remission for nine years — and now treats strangers for free.
ResearchFour myeloma studies accepted at IMS 2026, focused on the hardest groups — extramedullary disease and secondary plasma cell leukaemia.
TrialA Phase III trial of Equecabtagene autoleucel for relapsed or refractory myeloma that has stopped responding to lenalidomide (registered CTR20241656).
ResearchTwo oral presentations, sixteen posters and an e-poster — a snapshot of how deep the CAR-T and transplant caseload runs at a single centre.
ResearchIn 53 WT1-mutated patients, relapse rather than graft failure drove transplant failure — an argument for tighter post-transplant monitoring.
ResearchPublished in Frontiers in Immunology: donor selection may need to move beyond HLA matching to the family's inherited genetic background.
Beijing
A lymphoma and cell-therapy centre that publishes de-identified case reviews, including what to do when standard CAR-T has already failed.
A 68-year-old with stage IVB, IPI 5 CD5-positive DLBCL and double expression went from multi-line resistance to complete metabolic response.
CAR-TAfter a CD20 CAR-T and then a CD19/PD1/CD28 CAR-T both failed, a stepwise bispecific sequence brought refractory DLBCL back under control.
ResearchA plain-language science note on what an IND clearance does and does not mean for a new CD19 CAR-T in relapsed B-cell lymphoma.
Patient storyPMBCL grows fast and looks alarming on imaging, but with the right sequence it is one of the more curable large B-cell lymphomas.
Foshan, Greater Bay Area
The hospital closest to the manufacturing side of Chinese CAR-T, with its own international medical centre and cell-therapy programme.
Five-year follow-up, a landmark second-line result and Chinese real-world evidence: axicabtagene ciloleucel is edging large B-cell lymphoma toward cure.
CAR-TChina's first approved CAR-T has now treated more than 1,500 patients with relapsed lymphoma; the very first is still cancer-free after eight years.
CAR-TThe first T-cell collection in the Greater Bay Area for CT041 (satri-cel), for a gastric cancer patient previously treated in Mongolia and South Korea.
ResearchA BCMA/CD19 dual-target CAR-T has received implicit CDE approval for relapsed or refractory light-chain amyloidosis, where options are close to none.
ResearchLocalised manufacturing, registration and commercialisation in the Kingdom — Chinese cell therapy exported as a product, not just a treatment.
Shanghai
An international hospital whose cancer centre has become the most visible entry point for foreign patients seeking solid-tumour CAR-T.
On 6 July 2026 a 59-year-old from New Zealand became the first foreign patient to complete T-cell collection for CT041 in China.
Patient storyJosh went home on 16 August after more than a month of treatment — the first international patient to finish CT041 therapy at Jiahui.
Patient storyA 36-year-old from Quetta arrived after his lymphoma had been treated as a terminal illness, and left with a treatment plan that worked.
CAR-THow one target came to dominate gastric cancer: an antibody with a price cut, and a CAR-T built on the same biology.
CAR-TA national leader in cellular immunotherapy and stem-cell transplantation, with four decades in haematology, now leads the cancer centre.
Shanghai
One of the earliest Shanghai hospitals to build a CAR-T pathway designed end to end for patients coming from abroad.
A single coordinated route into CAR-T for foreign patients — eligibility review, apheresis, infusion and follow-up, with visa and insurance timing built in.
Patient storyA myeloma patient from the UK and a high-risk lymphoma patient were treated and discharged, with follow-up confirming the response.
Guangzhou
A cancer centre in southern China that handles the logistics of a long-distance treatment journey as carefully as the medicine.
Beijing
A paediatric haematology centre where the Beijing Protocol for haploidentical transplant is standard care, not a last resort.
A 14-year-old with relapsed ETP-ALL had already been through CAR-T in Australia; Beijing offered a haploidentical transplant on the Beijing Protocol.
Patient storyFrom eight days old, transfusions kept him alive. Nine years later a transplant gave him a childhood outside the ward.
ResearchTwo paediatric haematology studies from the hospital's transplant team presented as posters in Stockholm.
TrialA multicentre, placebo-controlled trial of a thrombopoietin receptor agonist, enrolling roughly 60 children with chronic ITP across China.
Chongqing
A large private oncology group whose lymphoma follow-up archive goes back more than a decade.